• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Sensus Healthcare Appoints Eric Sachetta to its Board of Directors

    11/12/25 8:00:00 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care
    Get the next $SRTS alert in real time by email

    Seasoned financial executive brings leadership acumen, strategic growth expertise and a strong track record of operational excellence

    Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Eric Sachetta to the Company's Board of Directors. Mr. Sachetta is filling the vacancy that resulted from the passing of long-serving Director Bill McCall.

    Throughout his career, Mr. Sachetta has held a range of leadership roles focused on organizational growth, team development, sales performance and operational improvement. He currently serves as Chief Wealth Services Officer of Sachetta, LLC, a financial advisory firm based in Lynnfield, Mass., where he leads firmwide advisory strategy, operational oversight, financial planning innovation and multi-disciplinary client service execution. Since 2022 he has led and managed the firm's financial advisory division, overseeing all wealth management operations and mentoring emerging advisors to achieve production goals.

    Earlier in his career he founded and led The E TEAM, a nationwide motivational speaking and leadership development organization that reached more than 140 schools and youth programs across 12 states. He also served as author and curriculum creator for "The 8 Mandates of Personal Leadership," a personal development framework used by students and coaches across the U.S.

    "I have been closely following Sensus Healthcare for many years and am impressed with the company's commitment to patient care and superior clinical outcomes through the delivery of non-invasive treatments for non-melanoma skin cancer and keloids," said Mr. Sachetta. "Sensus has an outstanding leadership team and I look forward to contributing to the long-term success of the company."

    "We are delighted to welcome Eric to our Board and look forward to his contributions," said Joe Sardano, Chairman and Chief Executive Officer of Sensus Healthcare. "Eric brings a strong financial background, deep experience leading organizations through growth and transition and a clear appreciation for the mission of our company. We believe that his combination of strategic insight and people-focused leadership will add meaningful value as we continue expanding the reach of our SRT technology and advancing our global vision."

    Mr. Sachetta holds a Bachelor of Science in Corporate Finance & Accounting from Bentley University. He is a Certified Financial Planner (CFP®), Chartered Financial Consultant (ChFC®), Tax Planning Certified Professional (TPCP™) and holds a Series 65 investment advisory license.

    About Sensus Healthcare

    Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com.

    Forward-Looking Statements

    This press release includes statements that are, or may be deemed, ''forward-looking statements.'' In some cases, these statements can be identified by the use of forward-looking terminology such as "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximately," "potential" or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words.

    Forward-looking statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus, our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. In addition, even if future events, developments, and circumstances are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this press release, as a result of the following factors, among others: the possibility that inflationary pressures continue to impact our sales; the level and availability of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; the development by others of new products, treatments, or technologies that render our technology partially or wholly obsolete; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes and costs; the risks arising from doing business in China and other foreign countries; legislation, regulation, or other governmental action that affects our products, taxes, international trade regulation, or other aspects of our business; the performance of the Company's information technology systems and its ability to maintain data security; our ability to obtain and maintain the intellectual property needed to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; and other risks described from time to time in our filings with the Securities and Exchange Commission, including our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.

    Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release, except as may be required by applicable law. You should read carefully our "Introductory Note Regarding Forward-Looking Information" and the factors described in the "Risk Factors" section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251112698767/en/

    Alliance Advisors IR

    Tirth T. Patel

    [email protected]

    212-201-6614

    Get the next $SRTS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SRTS

    DatePrice TargetRatingAnalyst
    1/31/2025$18.00Buy
    Lake Street
    11/15/2024$12.00 → $14.00Buy
    Maxim Group
    3/3/2022$12.00 → $13.00Buy
    HC Wainwright & Co.
    2/14/2022$10.00 → $12.00Buy
    HC Wainwright & Co.
    12/2/2021$9.00 → $10.00Buy
    HC Wainwright & Co.
    11/5/2021$7.00 → $9.00Buy
    HC Wainwright & Co.
    8/6/2021$6.00 → $7.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SRTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sensus Healthcare Expands Role of President Michael Sardano to Include Chief Commercial Officer

    New responsibilities recognize Mr. Sardano's significant accomplishments in securing CPT® codes for office-based SRT and the growing commercial opportunity the Company now faces Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced that President Michael Sardano has been appointed to the additional role of Chief Commercial Officer. In this newly created position, Mr. Sardano will direct the company's global sales, marketing and commercial strategy across its portfolio of SRT technologies, Sentinel® software and rela

    11/14/25 8:00:00 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Sensus Healthcare Appoints Eric Sachetta to its Board of Directors

    Seasoned financial executive brings leadership acumen, strategic growth expertise and a strong track record of operational excellence Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Eric Sachetta to the Company's Board of Directors. Mr. Sachetta is filling the vacancy that resulted from the passing of long-serving Director Bill McCall. Throughout his career, Mr. Sachetta has held a range of leadership roles focused on organizational growth, team development, sales performance and operation

    11/12/25 8:00:00 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Sensus Healthcare Reports Third Quarter 2025 Financial Results

    Centers for Medicare & Medicaid Services (CMS) established coding validating superficial radiotherapy (SRT) for treating non-melanoma skin cancer Revenues of $6.9 million Shipped 16 SRT systems including three to China Fair Deal Agreement (FDA) treatment volume increased 20% over the second quarter Exited the quarter with $24.5 million in cash and no debt Conference call begins at 4:30 p.m. Eastern time today Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and nine months end

    11/6/25 4:05:00 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    $SRTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Sachetta Eric bought $27,510 worth of shares (7,000 units at $3.93), increasing direct ownership by 5% to 140,113 units (SEC Form 4)

    4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

    11/21/25 2:28:31 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Director Sachetta Eric bought $11,250 worth of shares (2,500 units at $4.50), increasing direct ownership by 2% to 133,113 units (SEC Form 4)

    4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

    11/20/25 2:03:11 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    New insider Sachetta Eric claimed ownership of 132,706 shares (SEC Form 3)

    3 - Sensus Healthcare, Inc. (0001494891) (Issuer)

    11/20/25 1:55:42 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    $SRTS
    SEC Filings

    View All

    Sensus Healthcare Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Sensus Healthcare, Inc. (0001494891) (Filer)

    11/13/25 10:06:55 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Sensus Healthcare Inc.

    10-Q - Sensus Healthcare, Inc. (0001494891) (Filer)

    11/12/25 2:56:42 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Sensus Healthcare Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Sensus Healthcare, Inc. (0001494891) (Filer)

    11/6/25 4:15:45 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    $SRTS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Sachetta Eric bought $27,510 worth of shares (7,000 units at $3.93), increasing direct ownership by 5% to 140,113 units (SEC Form 4)

    4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

    11/21/25 2:28:31 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Director Sachetta Eric bought $11,250 worth of shares (2,500 units at $4.50), increasing direct ownership by 2% to 133,113 units (SEC Form 4)

    4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

    11/20/25 2:03:11 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    CHIEF EXECUTIVE OFFICER Sardano Joseph C bought $100,750 worth of shares (25,000 units at $4.03), increasing direct ownership by 2% to 1,200,293 units (SEC Form 4)

    4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

    11/19/25 9:34:10 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    $SRTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Sensus Healthcare with a new price target

    Lake Street initiated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $18.00

    1/31/25 9:07:11 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Maxim Group reiterated coverage on Sensus Healthcare with a new price target

    Maxim Group reiterated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $14.00 from $12.00 previously

    11/15/24 8:09:06 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    HC Wainwright & Co. reiterated coverage on Sensus Healthcare with a new price target

    HC Wainwright & Co. reiterated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $13.00 from $12.00 previously

    3/3/22 6:32:52 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    $SRTS
    Financials

    Live finance-specific insights

    View All

    Sensus Healthcare Reports Third Quarter 2025 Financial Results

    Centers for Medicare & Medicaid Services (CMS) established coding validating superficial radiotherapy (SRT) for treating non-melanoma skin cancer Revenues of $6.9 million Shipped 16 SRT systems including three to China Fair Deal Agreement (FDA) treatment volume increased 20% over the second quarter Exited the quarter with $24.5 million in cash and no debt Conference call begins at 4:30 p.m. Eastern time today Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and nine months end

    11/6/25 4:05:00 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Sensus Healthcare to Report Third Quarter 2025 Financial Results and Hold Business Update Conference Call on November 6

    Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report financial results for the third quarter of 2025 on Thursday, November 6, 2025. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a unique dial-in number to bypass the live operator. Participants may pre-register at any time, including up to and after the cal

    10/23/25 8:00:00 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Sensus Healthcare Reports Second Quarter 2025 Financial Results

    Shipped 19 SRT systems during the quarter, including four to China Revenues of $7.3 million FDA treatment volume increased 27% over the first quarter Exited the quarter with $22.2 million in cash and no debt Proposed Physician Fee Schedule expected to favorably impact adoption of SRT technology beginning in 2026 Conference call begins at 4:30 p.m. Eastern time today Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and six months ended June 30, 2025. Highlights of the

    8/7/25 4:05:00 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    $SRTS
    Leadership Updates

    Live Leadership Updates

    View All

    Sensus Healthcare Appoints Eric Sachetta to its Board of Directors

    Seasoned financial executive brings leadership acumen, strategic growth expertise and a strong track record of operational excellence Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Eric Sachetta to the Company's Board of Directors. Mr. Sachetta is filling the vacancy that resulted from the passing of long-serving Director Bill McCall. Throughout his career, Mr. Sachetta has held a range of leadership roles focused on organizational growth, team development, sales performance and operation

    11/12/25 8:00:00 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Sensus Healthcare Celebrates Skin Cancer Awareness Month by Promoting Awareness and Spotlighting its Patient-Friendly, Non-Invasive Treatments

    Innovative SRT-100 Vision (IG-SRT) and SRT Vision Technologies allow dermatologists to treat non-melanoma skin cancer without surgery or patient downtime May is Skin Cancer Awareness Month and Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, is leveraging a wide range of activities to draw attention to the importance of prevention, early detection and treatment of the most common form of cancer that affects millions of people worldwide. Throughout the month of May, Sensus Healthcare is actively promoting skin cancer awareness

    5/1/25 4:30:00 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Sensus Healthcare Announces Retirement of Director Samuel O'Rear

    BOCA RATON, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) --  Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that Samuel O'Rear will not stand for reelection to the Company's Board of Directors at the Company's 2024 annual meeting of stockholders.  Mr. O'Rear has been a Director of Sensus Healthcare since 2012. As previously announced, on January 11, 2024 the Board of Directors of Sensus Healthcare appointed Michael J. Sardano, President and General Counsel of Sensus Healthcare, as a Director, effective today. "Sam has been inv

    2/1/24 8:00:00 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    $SRTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Sensus Healthcare Inc. (Amendment)

    SC 13G/A - Sensus Healthcare, Inc. (0001494891) (Subject)

    2/6/24 12:27:47 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Sensus Healthcare Inc. (Amendment)

    SC 13G/A - Sensus Healthcare, Inc. (0001494891) (Subject)

    2/10/23 11:51:22 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Sensus Healthcare Inc. (Amendment)

    SC 13G/A - Sensus Healthcare, Inc. (0001494891) (Subject)

    2/7/22 8:30:08 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care